AGAMREE® (vamorolone) Data Presented at MDA 2026 Confirm Comparable Long-Term Effectiveness for up to 8 Years of Treatment, with Clinically Meaningful Safety Advantages in Duchenne Muscula...
Catalyst Pharmaceuticals, Inc. (CPRX)
Last catalyst pharmaceuticals, inc. earnings: 3/16 05:26 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.catalystpharma.com
Company Research
Source: Yahoo! Finance
Santhera Pharmaceuticals Holding AG Comparable long-term effectiveness to classic corticosteroids, both prednisone (p=0.8587) and deflazacort (p=0.6544), based on time to loss of ambulation 80% fewer patients with vertebral fractures (8.1% vs 41.9% on deflazacort, p=0.0082) Maintenance of normal height with 12.17 cm mean height advantage vs classic corticosteroids where significant stunting was observed (p Cataracts in 5.3% vs 37.8% patients, significantly lower than deflazacort (p=0.015); no glaucoma observed Pratteln, Switzerland, March 9, 2026 – Santhera Pharmaceuticals (SIX: SANN) today announced that full results from long-term real-world comparative analyses, including baseline data from the ongoing GUARDIAN study of AGAMREE® (vamorolone), were presented at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference 2026 in Orlando, Florida. The dataset includes up to eight years of AGAMREE exposure (median approximately five years) in boys with Duchen
Show less
Read more
Impact Snapshot
Event Time:
CPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CPRX alerts
High impacting Catalyst Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CPRX
News
- A Look At Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Softness [Yahoo! Finance]Yahoo! Finance
- Is Catalyst Pharmaceuticals (CPRX) Pricing Reflect Long Term Value After Rare Disease Interest? [Yahoo! Finance]Yahoo! Finance
- Catalyst Pharmaceuticals Touts Firdapse Growth, Agamree Traction as Fycompa Faces Generics [Yahoo! Finance]Yahoo! Finance
- Full Year 2025 Trading Update [Yahoo! Finance]Yahoo! Finance
- Catalyst Pharmaceuticals, Inc. (CPRX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
CPRX
Earnings
- 2/25/26 - Beat
CPRX
Sec Filings
- 3/19/26 - Form 8-K/A
- 3/18/26 - Form 8-K
- 2/25/26 - Form 8-K
- CPRX's page on the SEC website